Refreshing results…
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA
UploadHigh total metabolic tumor volume at baseline predicts survival independent of response to therapy
UploadMissing publications? Search for publications with a matching author name.